Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q2 FY26 results · Jul–Sep 2025
Supriya Lifescience reported revenue from operations of ₹199.83 crore (up 20.3% from Q2 FY25) and net profit of ₹50.43 crore (up 9.3% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 199.83 | 166.10 | +20.3% | 145.07 | +37.7% |
| Other income | 2.73 | 2.52 | +8.2% | 2.67 | +1.9% |
| Total income | 202.56 | 168.62 | +20.1% | 147.75 | +37.1% |
| Profit before tax | 68.32 | 62.06 | +10.1% | 47.41 | +44.1% |
| Net profit for the period | 50.43 | 46.15 | +9.3% | 34.79 | +44.9% |
| EPS, basic (₹) | 6.27 | 5.71 | +9.8% | 4.32 | +45.1% |
| Net margin (%) | 25.2 | 27.8 | 24.0 |
Standalone
- Filed with BSE
- 12 Nov 2025, 17:39 IST
- Board meeting
- 12 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE